Compare INM & ORIS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INM | ORIS |
|---|---|---|
| Founded | 1981 | 2014 |
| Country | Canada | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Farming/Seeds/Milling |
| Sector | Health Care | Consumer Staples |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7M | 3.7M |
| IPO Year | N/A | 2024 |
| Metric | INM | ORIS |
|---|---|---|
| Price | $1.24 | $0.07 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 145.5K | ★ 2.5M |
| Earning Date | 02-11-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.00 |
| Revenue | $4,798,116.00 | ★ $12,317,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $189.52 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.13 | $0.07 |
| 52 Week High | $8.27 | $2.85 |
| Indicator | INM | ORIS |
|---|---|---|
| Relative Strength Index (RSI) | 42.95 | 23.67 |
| Support Level | $1.18 | $0.07 |
| Resistance Level | $1.35 | $0.11 |
| Average True Range (ATR) | 0.10 | 0.01 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 28.13 | 4.31 |
InMed Pharmaceuticals Inc is a Canada based clinical-stage biopharmaceutical company. The Company's operations consist of two operating and reportable segments, the InMed Pharma segment and the BayMedica Commercial segment. The InMed Pharma segment is largely organized around the research and development of small molecule pharmaceuticals drug candidates and the BayMedica Commercial segment is largely organized around manufacturing technologies to produce and commercialize bulk rare cannabinoids for sale as ingredients in the health and wellness industry. Its product portfolio includes INM-755, which is used for the treatment of epidermolysis bullosa; INM-088 for the treatment of glaucoma; INM-901 for Alzheimer's disease.
Oriental Rise Holdings Ltd is an integrated supplier of tea products in China. It is principally engaged in the business of planting, cultivating, processing, and selling processed tea. The company currently produces and sells three categories of products: roughly processed white tea, roughly processed black tea, and refined tea. The company's business operations are vertically integrated, covering cultivation, processing of tea leaves, and the sale of tea products to tea business operators and end-user retail customers. Geographically, the company generates all of its revenue from its business in the People's Republic of China (the PRC).